Diffuse, Large B-Cell, Lymphoma Clinical Trial
Official title:
Multicenter Randomized Phase II Study of Treatment With R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting
for between 30% and 50% of the patients. Although it is considered a curable disease, still
at least 40 % of the patients will fail first line chemotherapy. The International Prognostic
Index (IPI) score and the age adjusted IPI (aIPI) has been used since they were published to
identify patients with different outcome.
There is not standard therapy for young patients with DLBCL and unfavourable IPI score. The
survival of these patients remains poor, with EFS around 40%.
The combination of RCHOP with new drugs is an attractive approach to treat these patients.
The goal is to evaluate the proportion of patients with Event-Free Survival (EFS) after 2
years, with a diagnosis of DLBCL with an aIPI > 1 or an aIPI =1 with increased levels of
beta-2-microglobulin (above the Upper Limits of Normal.)
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting
for between 30% and 50% of the patients. Although it is considered a curable disease, still
at least 40 % of the patients will fail first line chemotherapy. The International Prognostic
Index (IPI) score and the age adjusted IPI (aIPI) has been used since they were published to
identify patients with different outcome.
CHOP chemotherapy administered every 21 days has been for years the standard therapy for
advanced DLBCL achieving a long term overall survival (OS) of about 40%. Many studies show
that the addition of the monoclonal antibody Rituximab improves the patients survival
achieving higher rates of event-free survival in elderly patients with both,favourable and
unfavourable IPI score. R-CHOP also improved survival in young patients with favourable IPI
score.
There is not standard therapy for young patients with DLBCL and unfavourable IPI score. The
survival of these patients remains poor, with EFS around 40%.
The combination of RCHOP with new drugs is an attractive approach to treat these patients.
The investigators propose a phase II randomized clinical trial for young patients with
unfavourable IPI score DLBCL using 6 cycles of the combination of subcutaneous Bortezomib
with R-CAP (RCHOP without vincristine, to avoid neuropathy) comparing with the standard
immunochemotherapy regimen R- CHOP every 21 days.
The goal is to evaluate the proportion of patients with Event-Free Survival (EFS) after 2
years, with a diagnosis of DLBCL with aIPI > 1 or aIPI =1 with increased levels of
beta-2-microglobulin (above the Upper Limits of Normal).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02871869 -
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
|
Phase 2/Phase 3 | |
| Terminated |
NCT02374424 -
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
|
Phase 2 | |
| Completed |
NCT02391116 -
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
Phase 2 | |
| Terminated |
NCT04236141 -
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
|
Phase 3 | |
| Completed |
NCT00599170 -
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT02867566 -
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
|
Phase 3 | |
| Terminated |
NCT02855359 -
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
|
Phase 2 | |
| Completed |
NCT02216890 -
Safety Study of SGN-CD70A in Cancer Patients
|
Phase 1 | |
| Active, not recruiting |
NCT01181271 -
Tandem Auto-Allo Transplant for Lymphoma
|
Phase 2 |